Undrdose of immune chkpt inhibtr/immunostim drugs, sequela

This code signifies a long-term or residual effect resulting from a patient receiving an insufficient dose of immune checkpoint inhibitors or other immunostimulant medications. These drugs are typically used in cancer treatment to enhance the body's immune response against malignant cells. The underdosing could lead to suboptimal therapeutic outcomes or disease progression.

Apply this code when documenting a condition or complication that is a direct consequence of a past underdosing event of immune checkpoint inhibitors or immunostimulants. This is appropriate for chronic issues, persistent disease, or new problems arising months or years after the initial underdosing occurred. It should be used when the acute underdosing event is no longer being treated.

• Always sequence this code after the code(s) identifying the specific sequela (e.g., recurrent malignancy, persistent autoimmune reaction).
• Ensure documentation clearly links the current condition to a previous underdosing of the specified drug classes.
• Do not use for acute underdosing events; this code is exclusively for sequelae.